Articles
26.05.2021
Better internal communications

4 ways to improve market access through communication

Read more
Articles
21.05.2021
Cross-functional collaboration

There is a large opportunity many companies are still yet to seize in this area.

Read more
Articles
20.05.2021
What is HST

NICE’s Highly-Specialised Technologies (HST) process is a method for evaluating medicines and trea...

Read more
Articles
12.05.2021
NICE 5-year strategy

NICE has set out its plan using four key pillars designed to elicit incremental change within the UK...

Read more
Articles
11.05.2021
Market access training for speciality products

Securing patient access in specialty products is becoming increasingly challenging due to the comple...

Read more
Articles
04.05.2021
What is the difference between RWE & RWD

Real-world evidence (RWE) is increasingly playing an important role in developing product value prop...

Read more
Articles
28.04.2021
Managed access agreements NICE process

The highly specialised technologies (HST) process was introduced in 2013 for the purpose of evaluati...

Read more
Articles
12.04.2021
Benefits of early dialogue with HTA

Remap Consulting has significant expertise in guiding companies through both EUnetHTA / EMA Parallel...

Read more
Articles
31.03.2021
Recent changes to Italian P&R

Within the last few months, the significant changes proposed to the Italian pricing and reimbursemen...

Read more
Articles
29.03.2021
What is Relative Effectiveness Assessment

Relative Effectiveness Assessment (REA) is a type of assessment that evaluates the effectiveness of ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.